Drugs / Yangxinshi
Yangxinshi
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03333499 | Nov 2017 → Dec 2018 | heart failure | Dalian University | Unknown | No outcome recorded |
| Phase 44 trials · 1 met primary | ||||||
| Phase 4 | NCT07110415 | Nov 2025 → Aug 2030 expected | coronary artery disorder, heart failure | SPH Qingdao Growful Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 4 | NCT06171061 | Dec 2023 → Dec 2025 overdue | coronary artery disorder | Shandong First Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT05978089 | Nov 2023 → Jun 2025 | coronary artery disorder | Dongzhimen Hospital, Beijing | Unknown | No outcome recorded |
| Phase 4 | NCT03809273 | Aug 2019 → Dec 2020 | — | Shenyang Northern Hospital | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YangXinShi | “under the brand name YangXinShi (YXS) on the prognosis in patients with chronic heart failure” NCT03333499 ↗ |
| Known as | Yangxinshi tablet | “The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day).” NCT05978089 ↗ |
| Known as | Yangxinshi tablets | “Yangxinshi tablets, an herbal-based oral medicine, relieve symptoms of angina” PMID 39566404 ↗ Nov 2024 |
| Known as | YXS | “under the brand name YangXinShi (YXS) on the prognosis in patients with chronic heart failure” NCT03333499 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “traditional Chinese medicinal mixture under the brand name YangXinShi (YXS)” NCT03333499 ↗ |
| Route | Oral | “participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure” NCT03333499 ↗ |